{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.2676","upperLimit":"0.6946","value":"0.5000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"* Chronic GVHD rate and severity for the first 365 days after PBSC infusion will be assessed based on the NIH criteria\n* The cumulative incidence of chronic GVHD was determined using competing risk analysis. Competing risks for acute GVHD were death, relapse, and graft failure.","dispersionType":"95% Confidence Interval","groups":[{"description":"-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10\\^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10\\^6 CD34+ cells/kg and at least ≥ 2 x 10\\^6 CD34+ cells/kg from the combined collections.","id":"OG000","title":"Arm 1: Donors"},{"description":"-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0","id":"OG001","title":"Arm 2: Recipients"}],"paramType":"NUMBER","populationDescription":"-Donors are not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From Day 100 through 1 year after transplantation","title":"Cumulative Incidence of Chronic GvHD in Patients Who Have Undergone Transplantation of Hematopoietic Cells Mobilized With BL-8040 (Arm 2 Recipients Only)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}